Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human interleukin 21 + rituximab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Recombinant human interleukin 21 + rituximab is a combination therapy investigated for the treatment of indolent B-cell malignancies such as follicular lymphoma (FL), small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL), and marginal zone lymphoma. Recombinant human interleukin-21 (rIL-21) is a cytokine that enhances immune effector function, particularly by activating natural killer (NK) cells and cytotoxic T cells. Rituximab is a monoclonal antibody targeting CD20 on B cells, leading to their depletion via mechanisms including antibody-dependent cellular cytotoxicity (ADCC). The combination aims to improve anti-tumor efficacy by leveraging rIL-21’s ability to enhance NK cell-mediated ADCC and direct antiproliferative effects on some B-cell malignancies. Clinical studies have shown that this regimen can be administered safely in an outpatient setting with evidence of durable remissions in some patients[1][2][3][4][6].
- Brand names
- Rituxan
- Other names
- rIL-21 + rituximabrecombinant IL-21 + rituximabrhIL-21 + rituximab
02
Targets
CD20 (B-lymphocyte antigen CD20)IL21R (Interleukin-21 receptor)
Beyond the preview
Go deeper on recombinant human interleukin 21 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human interleukin 21 + rituximab.